Tag: gluten sensitivity
AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study
— Lead product AMYNOPEP achieves proof-of-principle in exploratory clinical study
— AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical enzymes on the lining of the intestinal brush border
AMYRA Biotech AG (“AMYRA”), a company developing novel, oral digestive enzyme therapeutics for gastrointestinal diseases announced the peer-reviewed publication of its clinical proof-of-principle study with its lead product AMYNOPEP in Frontiers in Immunology – Nutritional Immunology(https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1425982/full). AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical endogenous enzymes on the lining of the small intestine. AMYNOPEP is designed to break down hard-to-digest gluten peptides into harmless and absorbable single amino acids and dipeptides, thereby supporting individuals with gluten-related health disorders in avoiding exposure to inflammatory peptides. Read more…